Literature DB >> 20877018

Lichen planus treated with betamethasone oral mini-pulse therapy.

K K Verma1, R Mittal, Y Manchanda.   

Abstract

Ten Patients, 6 males and 4 females between 7-60 years of age having lichen planus for I month to 2 years were treated with betamethasone 5mg orally on two consecutive days in a week for 3 months. There was excellent (75-100%) response in 6 (60%) patients and good (50-75%) in 4 (40%) patients. None of the patients had significant side effects of the therapy and there were no treat-ment failures. Betamethasone on two consecutive days in a week as oral mini pulse therapy may be a safe, effective and a better therapeutic alternative for the treatment of lichen planus.

Entities:  

Year:  2000        PMID: 20877018

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  5 in total

1.  Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy.

Authors:  K Verma; K K Verma
Journal:  Indian J Pediatr       Date:  2001-04       Impact factor: 1.967

2.  Bullous Lichen Planus treated with Oral Minipulse Therapy: A Rare Case Report.

Authors:  Kotya Naik Maloth; K Sunitha; Ramanaryana Boyapati; Shravan Kumar D R
Journal:  J Clin Diagn Res       Date:  2014-12-05

3.  Weekly Azathioprine Pulse versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate-to-Severe Alopecia Areata.

Authors:  Prashant Gupta; Kaushal K Verma; Sujay Khandpur; Neetu Bhari
Journal:  Indian J Dermatol       Date:  2019 Jul-Aug       Impact factor: 1.494

4.  Childhood vitiligo: response to methylprednisolone oral minipulse therapy and topical fluticasone combination.

Authors:  Imran Majid; Qazi Masood; Iffat Hassan; Dilshad Khan; Muzammil Chisti
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

5.  Relapse after methylprednisolone oral minipulse therapy in childhood vitiligo: a 12-month follow-up study.

Authors:  Imran Majid; Saher Imran
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.